1270 / 1544
Name I Folie 1 I Datum
Synopsis
Nothing is clear for low risk CAP
High doses are needed to control intermediate and high dose CAP
The role of adjuvant pelvic RT is unclear
RT of manifest LN-Metastases is being evaluated, impact on therapy-free interval
or survival is unclear
Salvage RT results in >>50% secondary biochemical relapse free survival and
~50% long term OS
Hypofractionation is gaining traction, initial results are encouraging, tight margins
are neede to control toxicity, We may have to rethink dose volume constraints